[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:colorectal-adenocarcinoma:mrc1-wt-allele":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Colorectal Adenocarcinoma","MRC1 wt Allele",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07082439","Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma",[12],"Phase 2","RECRUITING","2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.856382Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07147231","Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:46.948970Z","2026-05-05T02:43:27.838424Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06529523","Tislelizumab in People With Colorectal Cancer",[12],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:27.088777Z"]